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ABSTRACT 
Malignant melanoma is a tumor characterized by a very high level of heterogeneity, responsible for 
its malignant behavior and ability to escape from standard therapies. In this review we highlight the 
molecular and biological features of the subpopulation of cancer stem cells (CSCs), well known to 
be characterized by self-renewal properties, deeply involved in triggering the processes of tumor 
generation, metastasis, progression and drug resistance. From the molecular point of view, 
melanoma CSCs are identified and characterized by the expression of stemness markers, such as 
surface markers, ATP-binding cassette (ABC) transporters, embryonic stem cells and  intracellular 
markers. These cells are endowed with different functional features. In particular, they play pivotal 
roles in the processes of tumor dissemination, epithelial-to-mesenchymal transition (EMT) and 
angiogenesis, mediated by specific intracellular signaling pathways; moreover, they are 
characterized by a unique metabolic reprogramming. As reported for other types of tumors, the 
CSCs subpopulation in melanoma is also characterized by a low immunogenic profile as well as by 
the ability to escape the immune system, through the expression of a negative modulation of T cell 
functions and the secretion of immunosuppressive factors. These biological features allow 
melanoma CSCs to escape standard treatments, thus being deeply involved in tumor relapse. 
Targeting the CSCs subpopulation is now considered an attractive treatment strategy; in particular, 
combination treatments, based on both CSCs-targeting and standard drugs, will likely increase the  
therapeutic options for melanoma patients. The characterization of CSCs in liquid biopsies from 
single patients will pave the way towards precision medicine. 
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1.  Introduction 
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Cutaneous melanoma represents one of the most aggressive forms of skin cancer: despite it 
accounts for less than 5% of all skin cancers, it is the cause of the majority (75%) of the skin 
cancer-related deaths [1]. The high level of heterogeneity of melanomas is responsible for the lack 
of pan-melanoma therapies (inter-tumor heterogeneity), thus resulting in the increasingly urgent 
need of the patient-focused precision medicine. On the other side, the intra-tumor heterogeneity is 
related to the existence of distinct subsets of cancer cells in the tumor bulk, thus leading to drug 
resistance [2]. Encouraging therapeutic strategies have been developed in recent years, but the 10-
years survival for metastatic melanoma is still less than 10%. 'Targeted therapies', such as 
vemurafenib (a BRAFV600E inhibitor), were developed in order to specifically target mutated 
proteins, with a response rate around 50%. However, most patients relapse within few months [3]. 
Similarly, the 'immune-checkpoint inhibitors', such as nivolumab (a PD-1 inhibitor) and ipilimumab 
(a CTLA-4 inhibitor), were developed to improve the endogenous antitumor immune response. 
However, they are effective on only a subset of patients, with a primary resistance higher than 50% 
and the development of acquired resistance in initially responders [4].  
   Two models have been used to explain melanoma heterogeneity. In the stochastic model, all 
tumor cells are equivalent and characterized by subclonal differences that result from differential 
genetic and epigenetic alterations during the development of cancer. In the hierarchical model, a 
small, slow-cycling subpopulation of cells called 'cancer stem cells' (CSCs) resides at the top of the 
hierarchy [5, 6]. The classical, idealized notion holds that CSCs are characterized by their limited 
number and their ability for self-renewal through asymmetric cell division, thus behaving as normal 
stem cells: on one side, a differentiated and rapidly proliferating daughter cell is generated, so that 
the tumor mass is consecutively formed, but on the other side, a new stem cell is renewed, 
providing the source for the continuous repopulation of the tumor bulk [7]. The two models are not 
mutually exclusive, because the progeny of differentiated cells could undergo to clonal evolution 
[5]. If the existence of a stemness state appears not to be questioned, the hierarchical organization of 
the tumor is a matter of debate. Recent evidences suggest that every cancer cell gains the potential 
to shift to a stem cell state, and this acquired phenotype could be reverted again toward a non-stem 
state, due to the high level of plasticity of the tumor cell [5]. This appears to be true especially for 
melanomas, where the existence of CSCs is well documented, as well as their role in tumor relapse 
after administration of chemotherapy and targeted therapies [8]. 
   This review will discuss the standard definition and characterization of melanoma stem cells, 
pointing to the skepticism related to their biomarkers. Their functional features and phenotypic 
plasticity will be presented, together with the consequent therapeutic implications. 
 
2.  Melanoma CSCs biomarkers 
 
   Accordingly to the classical definition of CSCs, i.e., a rare subpopulation of cells endowed of self-
renewal capacity and tumor-generating potential, the definitive demonstration of their existence 
resides in their ability to give rise to a tumor mass when serially transplanted at limited dilutions in 
vivo: a plethora of studies demonstrated the high tumorigenicity of CSCs in different types of 
cancers [9-13]. In order to reach such proof-of-concept, different methods have been developed and 
are currently exploited to isolate CSCs from patient-derived tumors or cancer cell lines in vitro. In 
particular, it has been demonstrated that a CSCs-enriched culture can be obtained through culturing 
the bulk of tumor cells in a stem cell-specific medium, thus allowing their selection and growth as 
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spherical colonies in suspension [12, 14]. A finest isolation can be obtained through fluorescence-
activated cell sorting (FACS), exploiting the expression of CSC-specific markers, leading to a pure 
population of CSCs [12, 15-17]. In this context, specific patterns of biomarker that identify CSCs 
have been defined for some tumors (i.e., CD44+/CD24-/low for breast cancer, 
CD44+/CD24+/ESA+/CD133+ for pancreatic cancer, CD133+ for glioma). Differently, the existence 
of a unique and specific biomarker signature for melanoma stem cells is still controversial, because 
of the high degree of plasticity of this tumor, and possibly of the existence of multiple mechanisms 
that lead to melanoma progression [18].       
   In the last decade, different biomarkers have been proposed for the identification of melanoma 
stem cells, but most of them were found to be expressed on different subclones, rather than 
restricted to the highly tumorigenic population of cells. An elegant study was performed by 
Quintana et al., where the tumorigenic potential of patient-derived tumor cells was analyzed in 
NOD/SCID IL2Rγnull mice, dependently on the differential expression of 22 putative melanoma 
stem cells markers. The authors demonstrated that none of them was able to significantly identify 
the stem cell subpopulation, since cells lacking those markers retain the tumorigenic ability [5]. 
   The markers commonly used are related to a melanocyte undifferentiation state (CD271, CD133), 
to mechanisms of drug resistance (ATP-binding cassette transporters, ABCs), or to metabolic 
features (ALDH activity) [19-21]. Other studies revealed the expression of embryonic stem cell 
markers, such as Sox2, Klf4, Oct4 and Nanog, as a common feature of CSCs derived from different 
tumors [22]. 
2.1. Surface markers 
Among the surface markers commonly and more consistently used to identify melanoma stem cells, 
CD271 (also known as p75) represents the most controversial. Since the low affinity receptor for 
the neurotrophin NGF (nerve growth factor) is mainly expressed in the neural crest during 
embryonic development, the expression of CD271 on melanoma cells could reflect a certain degree 
of undifferentiation, a typical feature of CSCs, beside their ability of multilineage differentiation 
under appropriate conditions. However, a very high variability is observed in the expression of this 
marker: it has been calculated that it can mark a subpopulation of melanoma cells ranging from 
2.5% to 40% [20], and conflicting results were obtained about the reliability of this marker [5, 23-
26]. However, other recent studies highlight how CD271 could be functionally involved in the 
aggressive features of melanoma cells [27-30] and in melanoma progression and prognosis [31, 32]. 
CD133 (Prominin-1) is a membrane protein originally identified in murine neuroepithelial stem 
cells and associated with primitive human cell differentiation, but its role in cancer cells is still 
unclear. It seems to be related to pathways of tumor progression and aggressiveness (epithelial-to-
mesenchymal transition, EMT; Wnt signaling pathway) [33] and, as such, it has been associated 
with CSCs in different tumors [34]. However, conflicting results have been reported regarding its 
role in defining the CSC population in melanoma tumors [21, 35, 36]. 
 
2.2. Markers associated with drug-resistance 
 
   The ATP-binding cassette (ABC) transporters are known to mediate multidrug resistance through 
drug efflux in cancer cells, a phenomenon usually associated with CSCs [37]. In particular, ABCB5 
was found to be a marker of melanoma stem cells, due to the higher tumorigenic ability of ABCB5+ 
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cells, to the correlation with tumor progression in melanoma patients and to the co-expression with 
other putative melanoma stem cell markers such as CD133 [38-41]. Similar results have been 
obtained for ABCG2 [42, 43], another ABC transporter associated with stemness in different 
tumors such as pancreatic cancer, melanoma and breast cancer. The identification of CSCs through 
ABCG2 is achieved by the expression of the transporter itself or by the analysis of its functionality: 
ABCG2 is able to favor the efflux of fluorescent dyes such as rhodamine 123, so that the cells 
expressing the transporter result negatively stained, and visualized on a flow cytometry plot as a 
“Side Population” adjacent to the ABCG2- cells [37]. Moreover, it has been demonstrated that the 
population of ABCG2-expressing cells is endowed of higher autofluorescence compared to the 
ABCG2- population, due to the accumulation of riboflavin in intracellular vesicles, in pancreatic 
cancer and in melanoma, so that the autofluorescence level itself could be exploited as a CSC 
marker [26, 44-46]. 
2.3. Intracellular markers 
   CSC intracellular markers comprise enzymes such as aldehyde dehydrogenases (ALDH), and 
transcription factors such as Sox2 and Klf4. 
   ALDHs are key enzymes involved in detoxification, converting aldehydes in their respective 
carboxylic acids. ALDH isozyme 1 (ALDH1) have been found to be overactivated in CSCs of 
different types of cancer, including melanoma, where the isoforms 1 (ALDH1A1) and 3 
(ALDH1A3) are correlated with CSC functions [47, 48]. It has been demonstrated that retinoic acid 
(RA), produced through the conversion of retinaldehyde, can lead to the expression of genes 
involved in CSC functions, mediated by its binding to the nuclear receptors RAR (retinoic acid 
receptor)  and RXR (retinoic X receptor) [47]. Methods for the identification of CSCs on the basis 
of their ALDH activity include Aldefluor® assay: BODIPY-aminoacetaldheyde (BAAA) is a 
fluorescent substrate that diffuse into viable cells and is converted to BOPDIPY-aminoacetate 
(BAA) by ALDH. BAA is negatively charged and retained inside the cell: the brightest signal 
(ALDHbr) is detectable by flow cytometry and is representative of the higher ALDH activity.  
   The embryonic transcription factors Sox2 and Klf4 are closely associated with CSC functions, 
reflecting their similarity with normal stem cells. They are considered as pluripotency markers, and 
their overexpression in melanoma cells drives the reprogramming toward a cancer stem cell 
phenotype, in terms of dedifferentiation, induction of cell proliferation, inhibition of apoptosis, 
tumor initiation and drug resistance [49-51]. 
   It is noteworthy that other putative markers, that could be generalized to different types of cancer, 
have been proposed for melanoma stem cells. However, they are more related to aggressiveness and 
adaptive/plasticity features of the whole cancer cell population (i.e., metabolic switch, EMT) rather 
than to specific CSC features such as undifferentiation or drug resistance.  
 
3.  Melanoma CSCs and tumor progression 
    
   Tumor progression is often accompanied by the ability of cancer cells to give rise to metastases, 
responsible for the majority of cancer associated deaths. According to the 'seed and soil' hypothesis 
[52], metastasis is a multi-step process in which a heterogeneous group of cells derived from the 
primary tumor mass (seed) acquires the ability to: escape from the original cancer tissue, spread into 
the surrounding tissue by invading the extracellular matrix, enter (intravasation) and travel through 
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the bloodstream (now called circulating tumor cells, CTCs) from which they finally exit 
(extravasation) and colonize distant sites (soil). To this purpose, it must be underlined that most of 
melanoma metastases involve lymph nodes and lungs [53].       
   Before disseminating, primary tumor cells undergo a phenotypic conversion characterized by the 
acquisition of EMT features. This process is characterized by peculiar changes of the expression 
levels of cell-matrix or cell-cell adhesion molecules (i.e., integrins, cadherins, EpCAM, 
cytokeratins) [54]. Once reached the secondary site, disseminated cancer cells must undergo a 
reversal of the EMT toward a MET (mesenchymal-to-epithelial transition) phenotype in order to 
give rise to a manifest metastasis; at the metastasis level, CTCs also enter a dormancy state likely 
associated with the quiescent characteristic of CSCs [8, 55]. 
   The presence of CTCs in liquid biopsies, such as blood, of cancer patients plays a key role in 
tumor diagnosis and, therefore, in the prevention of cancer progression [56-58].  
   During the last years, growing evidence from the literature has strongly demonstrated that CSCs 
are deeply involved in the growth and dissemination of tumors, including melanoma [8, 58-61]. 
This evidence is mainly based on the presence of cells expressing stemness markers both in the 
circulation and at the metastatic sites. First, it has been shown that a multi-marker analysis can 
increase the isolation of CTCs from the blood of melanoma patients, although a high heterogeneity 
exists among these cells in terms of specific marker expression; importantly, CTCs with different 
markers expression differentially respond to standard treatments [62].  
   As discussed above, the presence of surface markers (CD271, CD133), of  markers of drug 
resistance (ABCB5, ABCG2) and of intracellular markers (ALDH isozymes) was widely shown to 
be associated with increased tumorigenic properties of melanoma cells as well as with a high 
incidence of melanoma metastases and resistance to standard targeted therapies (i.e., vemurafenib) 
[8, 27, 32, 63-66].  
   Knockdown of stemness markers in melanoma cells suppresses their metastatic ability in vitro and 
in vivo (nude mice bearing melanoma xenografts) and potentiates the  anti-proliferative and anti-
metastatic activity of chemotherapeutic drugs [40, 67]. In line with these observations, Gray et al. 
demonstrated that the presence of cells expressing stemness markers in the blood of patients treated 
with standard targeted therapies is prognostic of a shorter progression-free survival [68].  
   As stated above, the process of EMT is a cell-biological program that plays a key role in tumor 
progession. Recent evidence strongly supports that two different EMT programs are activated in 
cancer progression. According to the classical theory, during the transition from the epithelial to the 
mesenchymal phenotype, neoplastic cells acquire specific mesenchymal features that allow them to 
loose their cell-matrix/cell-cell adhesion properties and to acquire migratory and invasive properties 
[69, 70], leading to the dissemination to distant sites and the initiation of macrometastases. On the 
other hand, in the last years it has become increasingly clear that the EMT is associated with a 
second crucial program based on the acquisition, by a subpopulation of the bulk of tumor cells, of 
the classical morphological, biological and functional CSC-like traits, such as stem cells superficial 
markers and self-renewal capacity, thus leading to the generation of CSCs [17, 71-74]. Thus, EMT 
is responsible not only for the acquisition of mesenchymal features by carcinoma cells but also for 
the de-differentiation of tumor cells into cells with CSCs traits. 
   It is now established that both EMT programs are triggered by different signals from the tumor 
microenvironment. Specifically, in cancer cells, biological factors secreted by tumor-associated 
stromal cells play a key role in inducing the expression of transcription factors that direct the EMT 
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programs (EMT-TFs) through activation of different intracellular signaling pathways [17]. 
Interestingly, cancer cells were shown to acquire CSC traits according to the specific EMT-TFs that 
are activated by these signals [17, 75]. In particular, the transcription factors Slug, Snail, Zeb, 
Twist, Sox, MITF (Melanogenesis-associated Transcription Factor) and ESRP1 (Epithelial Splicing 
Regulatory Protein1) were reported to be involved in the acquisition of CSC traits by melanoma 
cells. Specifically, Twist1 and Zeb1 (but not Twist2 and Zeb2) act as promoters of the acquisition 
of a CSC phenotype in melanoma cells, while the tumor levels of ESRP1 inversely correlate with 
the EMT transition in these cells [74-77].  
   In line with these observations, Zeb1 expression positively correlates with the expression levels of 
the CSCs markers CD133 and CD44 in murine melanoma cells (B16F10); on the other hand,  
silencing of this EMT-TF reduces the metastatic potential of melanoma stem cells. Moreover, by 
binding to the GLI2 transcription factor, Zeb1 suppresses the expression of the epithelial marker E-
cadherin in both murine and human melanoma cells [78, 79]. Moreover, silencing of the 
oncosuppressor Zeb2 significantly increases the expression of Zeb1 together with that of proteins 
related to the mesenchymal traits and metastatic behavior of melanoma cells, such as vimentin and 
fibronectin [80]. 
   In addition to these transcription factors, IGF-1 (insulin-like growth factor-1) expression has been 
shown to correlate with EMT transition and stemness traits in different cancer cells. IGF-1 is 
produced by both melanoma cells and melanoma microenvironment. Silencing of IGF-1 in murine 
B16F10 melanoma cells was found to decrease the expression levels of Zeb1, mesenchymal 
markers and stem cells markers (CD133, Sox2, Oct3/4): this effect was accompanied by a decrease 
in functional stemness markers (sphere formation, ALDH1 activity) [81]. Moreover, IGFBP5 
(Insulin-like Growth Factor Binding Protein 5) was reported to decrease the expression levels of 
stem cell markers in human melanoma cells (CD133, Sox2, Oct4) [82]. 
   Taken together, these data strongly support that: 1) CSCs are critical for the process of melanoma 
growth, dissemination and metastasis, and 2) cells with morphological, biological and functional 
traits of CSCs can be generated during the EMT transition through the de-differentiation of a 
subpopulation of the bulk of melanoma cells (Figure 1).  
   It is now well known that melanoma progression can also be associated with the so called 
'mesenchymal-to-ameboid' transition (MAT). During this process, melanoma cells acquire specific 
stemness markers together with an increased metastatic potential; this process seems to be strictly 
related to the expression of EphA2 (ephrin type-A receptor 2, a member of the Eph family of 
receptor tyrosine kinases) and RacN17 (a dominant-negative form of Rac1) [83]. 
 
4.  Melanoma CSCs and angiogenesis 
    
   The process of angiogenesis (i.e., the formation of new blood vessels) is a hallmark of the growth 
and progression of tumors, including melanoma [84]. Blood vessels provide oxygen and nutrients to 
tumor cells and, at the same time, facilitate their dissemination to distant sites in order to give rise to 
metastases. Different factors critically involved in the formation/maintenance of angiogenesis were 
shown to be expressed in melanomas, such as vascular endothelial growth factor (VEGF), 
particularly the isoforms VEGF165 and VEGF121, VEGF receptors (VEGFR), basic fibroblast 
growth factor (bFGF) and its receptors, platelet derived growth factor (PDGF) receptors, 
interleukins, matrix metalloproteinases, urokinase plasminogen activator, as reviewed by Jour and 
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coworkers [85]. Moreover, highly aggressive melanomas were reported to be characterized by the 
acquisition of an endothelial phenotype by the tumor cells themselves, enabling their participation 
in new vessel formation (i.e., vascular or vasculogenic mimicry).  
   Melanoma cells with stem cell-like traits, particularly located at the margin of the tumor (i.e., 
melanoma initiating cells), express and secrete in the microenvironment several factors associated 
with angiogenesis. In these cells, Lee and coworkers reported that α5β1 integrin, through its 
downstream target ERK, triggers angiogenesis and neovascularization by activating the STAT and 
HIF1α pathways [86]. Moreover, melanoma cells expressing the CD133 and ABCG2 stem cells 
markers were shown to overexpress proangiogenic proteins, such as VEGF and its receptor 
VEGFR-2, Tie2 and angiopoietin [42]. In line with these observations, it has been recently reported 
that melanoma stem cells positive for CD133 can induce neoangiogenesis, through the 
Notch1/MAPK signaling pathway and the subsequent increased expression of VEGF and matrix 
metalloproteinases MMP-2/-9 [87]. 
   Interestingly, CSCs (including melanoma stem cells) are characterized by a high level of 
differentiation plasticity that makes them able to trans-differentiate, thus acquiring an endothelial 
phenotype and inducing vessels formation. Based on this property, it is now accepted that these 
cells can directly contribute to the 'angiogenic switch' by forming an alternative microvascular 
circulation that allows tumor dissemination and metastasis. This process in known as 'vascular or 
vasculogenic mimicry' (VM) and is independent of endothelial cell-related angiogenesis [8, 88-90]. 
Melanoma CSCs positive for ABCB5 express specific endothelial and proangiogenic factors as well 
as VE-cadherin, Tie2, VEGF and its receptors, specific markers of VM [91]. In addition, CD133+ 
melanoma CSCs, shown to express proangiogenic factors, were found to trans-differentiate into 
endothelial-like cells and to be endowed with tube formation ability, the typical feature of vascular 
endothelial cells [87]. Similarly, CD271+ melanoma CSCs were reported to be associated with VM, 
through activation of the VEGR receptor/PKC signaling pathway [92, 93]. Syndecan-1, a cell 
surface heparan sulphate (HS) and chondroitin sulphate (CS) proteoglycan, has been shown to be 
deeply involved in the VM process of melanoma stem-like cells [94]. Melanoma cells made 
resistant to DNA-alkylating agents and expressing high levels of ABC transporters acquire an 
endothelial phenotype and trigger the VM process [95]. These results were further supported by 
data from in vivo studies. In particular, Zimmerer and coworkers, using in vivo fluorescence 
microscopy, demonstrated that CD133+ melanoma D10 cells, xenografted into nude mice, are able 
to trigger a significant angiogenesis process [96]. Very recently, VM induced by CSCs has been 
reported to be an interesting biological target of anticancer compounds (i.e., the natural 
phytochemical lupeol) in melanoma cells, both in vitro and in vivo [97]. 
   The classical angiogenesis process, together with the vasculogenic mimicry associated with cells 
displaying stemness traits, are recognized as the key events allowing intravasation of tumor cells 
and their dissemination to distant sites. Interestingly, in addition to the intravascular dissemination, 
a different mechanism has been recently proposed to play a key role in the spread of tumor cells, 
including melanoma cells. This process, known as 'angiotropism', is based on the ability of cancer 
cells to migrate moving along the abluminal vascular surface (extravascular vasation migratory 
metastasis, EVMM) without intravasation. In this way, tumor cells migrate in a pericytic-like 
manner ('pericytic mimicry') along the surface of blood vessels that represent a biological track for 
their long 'trip' towards distant metastatic sites [98, 99]. Interestingly, Lugassy and coworkers 
demonstrated that angiotropic melanoma cells moving along the abluminal vascular surface express 
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markers of stemness and resistance to therapy, such as the Platelet-Derived Growth Factor β 
(PDGFB) and its receptor [98].  
   The involvement of melanoma CSCs in tumor angigenesis is summarized in Figure 1. 
   Further studies are needed to confirm the involvement of melanoma CSCs in these mechanisms. 
 
5. Immunogenic properties of melanoma CSCs 
It has been demonstrated that CSCs are endowed of immunogenic features that lead to immune 
escape. The concept of tumor immunosurveillance arose in early 1900, when Paul Ehrlich and 
subsequently Lewis Thomas postulated that immune cells could recognize cancer cells and prevent 
tumor growth [100]. Supporting evidence is represented by the negative correlation existing 
between immunocompetence and cancer incidence: immunosuppressive states (i.e., following HIV 
infections and organ transplantations) have been closely associated with an increased risk of cancer 
development, independently of the specific type of tumor [101]. Immune-escaping events could 
bring cancer cells to evade the elimination mechanisms exerted by the host’s immune system. As 
long as the balance between evasion and elimination keeps the tumor in a dormancy state, tumor 
outgrowth is prevented. Additional escaping mechanisms, immune exhaustion, and the consequent 
expansion of evading clones lead to tumor initiation and progression [102, 103].   
   Immune cells can be activated against cancer cells due to the expression of tumor associated 
antigens (TAAs), that have been recognized and inversely correlated with the expression of 
stemness markers. TAAs can be classified into two categories:  
1. Differentiation antigens are usually expressed on normal cells, but are overexpressed by 
cancer cells, irrespectively of their lineage-specificity. MART-1 (Melanoma Antigen 
Recognized by T cells), tyrosinase, gp100 are examples of melanoma-associated antigens 
linked to the melanocytic lineage. On the other hand, cancer-testis antigens such as NY-
ESO1, MAGE-A3, MAGE-A4 are typically restricted to germ cells and placenta but their 
expression has been linked to melanoma.  
2. Neoantigens are restricted to tumor cells, because they originate from mutation events that 
generate new epitopes, such as the BCR-ABL fusion protein in leukemia.  
   Melanoma is generally recognized as a high immunogenic tumor, and this means that it can easily 
elicit antitumor immune responses and it is characterized by an important immune infiltrate 
involving innate cells in early phases and adaptive cells in late phases. However, the immune 
system is not effective in fighting tumor growth. This could be due to the existence of a 
subpopulation of cells in the tumor bulk endowed of low-immunogenic profile and/or of 
immunosuppressive abilities. These cells may be positively selected based on their immune-
privileged state and favor tumor progression [102-104].  
   CSCs show a low-immunogenic profile, since they are characterized by the downregulation of 
TAAs: it has been demonstrated that ABCB5+ melanoma cells do not express the immunogenic 
differentiation antigen MART-1 at significant levels [105], as well as they do not express cancer 
testis antigens [106]; similarly, CD271+ melanoma cells do not show the expression of both 
differentiation and cancer testis antigens [107, 108]. However, conflicting results do exist, since 
other studies demonstrated that CD133+ melanoma cells are able to induce a significant T cell 
response due to the overexpression of the NY-ESO1 antigen [109] and that melanoma stem cell-
based vaccination is able to elicit effective antitumor immune responses in murine melanoma 
models [110, 111]. 
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   The ability to escape the immune system could be achieved by defective antigen 
processing/presentation, despite the presence of immunogenic antigens. It has been demonstrated 
that melanoma stem cells show a 'defective' expression of molecules related to antigen presentation 
such as MCH class I molecules (Major Histocompatibility Complex-I) [105, 106, 112]. Even if 
antigens are presented correctly, in order to permit the full T cell activation, a costimulatory signal 
is necessary. On the contrary, T cell downregulation is achieved by a negative costimulation: 
melanoma stem cells can thus express molecules involved in the negative modulation of T cell 
activation, such as PD-L1, PD-1 and CD86, escaping the antitumor immune response [111, 113-
115]. Similarly, a protumor environment is promoted by the secretion of immunosuppressive 
molecules by cancer cells, or by the recruitment of protumor immune cells.      
   Cancer cells may directly induce T-, B- and NKs cell death (i.e. through FasL secretion). T cell 
inhibition is also favored by the secretion of selected cytokines such as IL4, IL10, TGFβ: it has 
been demonstrated that ABCB5+ melanoma cells are characterized by the upregulation of TGFβ-
related proteins [38]. Moreover, cancer cells can selectively recruit immune cells endowed of 
tumor-promoting abilities, especially favoring the expansion of cells belonging to the myelocytic 
lineage (myeloid-derived suppressor cells, granulocytes and macrophages), and their infiltration 
within the tumor mass [116]. The recruitment of T cells endowed of immunosuppressive properties 
such as regulatory T cells (T regs) and T helper cells (Th17) represent an additional mechanism by 
which melanoma cells can take advantage in order to shape the immune microenvironment toward a 
protumo setting. Whether the recruitment of these cells is related to melanoma stem cells rather than 
to a highly plastic subpopulation of cells is not clear yet, but intricate interconnections between 
melanoma cells and immune cells have been documented, together with the recruitment of specific 
protumor immune cell subsets and their role in resistance to immunotherapies [117-119].  
   The immunogenic properties of melanoma CSCs are shown in Figure 2. 
 
6. Melanoma CSCs and metabolic reprogramming 
 
   It is now well accepted that metabolic reprogramming represents a hallmark of neoplastic 
transformation in most types of cancer, including melanoma [120-122]. Cancer cells need high 
amounts of energy as well as of building blocks for the synthesis of new cellular components to 
support their growth and survival. In particular, cancer cells display increased activity of the 
glycolysis pathways, also in the presence of oxygen, with formation of pyruvate that is further 
converted into lactate. This phenomenon, accompanied by high levels of glucose uptake, was first 
described by Otto Warburg and is now referred to as the 'Warburg effect' [123]. On the other hand, 
in contrast to previous theories, it is now accepted that cancer cells can also possess functional 
mitochondria with increased oxidative phosphorylation (OXPHOS) with elevated 
expression/activity of the respiratory chain proteins and ATP production, accompanied by high 
oxygen consumption [124, 125]. Another aspect of the metabolic reprogramming in cancer cells is 
the high rate of fatty acid synthesis and of glutaminolysis, leading to the conversion of glutamine 
into glutamate to fuel the TCA cycle (tricarboxylic acid cycle) and into intermediates necessary for 
aminoacids and nucleotides synthesis [126, 127]. These pathways of metabolic rewiring were 
reported also in melanoma cells in which they were shown to be linked to the specific genetic 
mutations, based on the characteristic heterogeneity of this tumor [127-131]. 
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   CSCs need a high amount of energy for their functions, such as proliferation and evasion from the 
antitumor activity of chemotherapy; based on this observation, metabolic rewiring has been 
proposed as a hallmark also of CSC functions [125, 132, 133]. According to some reports, CSC 
metabolism is characterized by a high glycolytic profile, together with increased production of 
lactate; this allows CSCs to obtain ATP for their high energy demands as well as different 
metabolites necessary for the synthesis of novel molecules (aminoacids, lipids, nucleotides), thus 
supporting their survival and propagation. Stem cells from some tumor types (breast, hepatocellular 
carcinoma) were reported to express high levels of the glucose transporter GLUT1 as well as of the 
glycolytic enzymes together with low levels of enzymes involved in the gluconeogenic processes. 
On the other hand, increasing experimental evidence demonstrates that different cancer cells 
(ovarian, lung, pancreatic, prostate cancers) preferentially rely on mitochondrial OXPHOS to 
produce enough levels of ATP for their self-renewal and survival [134-139]. This increased 
OXPHOS activity was shown to be associated with increased mitochondrial mass (biogenesis) 
through increased expression of PGC1α [140, 141]. Taken together, these observations suggest that 
the dependence of CSCs on the glycolytic pathway vs. the OXPHOS metabolism may be related to 
the specific types of tumor cells.  
   Alterations of lipid metabolic pathways (i.e., increased intracellular lipid levels) was also reported 
to be associated with stemness features in tumor cells and to provide them the adequate amount of 
energy and metabolic intermediates necessary for their growth/survival [139, 142, 143]. For 
instance, increased activity of fatty acid synthase (Fasn), the key enzyme in the process of de novo 
lipid synthesis, as well as of enzymes involved in the mevalonate pathway (essential for cholesterol 
synthesis) were observed in different types of CSCs [144, 145]. On the other hand, CSCs were 
shown to rely on fatty acid oxydation (FAO) to obtain sufficient amounts of acetyl-CoA and NADH 
to fuel the subsequent production of ATP [146].  
   It is known that CSCs can obtain lipids from their microenvironment. Fatty acids can enter into 
CSCs, through the binding to their specific CD36 transporter expressed on their membranes, where 
they are broken down by β-oxidation to produce ATP [147]. In agreement with these findings, 
CSCs expressing the CD36 receptor and enzymes involved in lipid metabolism, were found to be 
characterized by increased fatty acids (i.e., palmitic acid) uptake together with increased self-
renewal/proliferation and metastatic behavior; the presence of CD36 positive cells is now 
considered a poor prognosis for different types of tumors [148].  
   In CSCs, lipids (fatty acids and cholesteryl esters) are stored into organelles known as 'lipid 
droplets' (LD), originating either from the Golgi or the endoplasmic reticulum membranes [144]; a 
positive correlation has been reported between lipid droplets content and stemness traits in CSCs 
from different types of cancers (colorectal, breast, ovarian); moreover, being released from cancer 
cells, the amount of lipid droplets in patients liquid biopsies (i.e., blood) is now considered an 
effective marker of tumor aggressiveness [149]. 
   CSCs also rely on glutamine (Glu) metabolism to sustain their energy formation and self-renewal. 
Extracellular glutamine is transported into the cells by its specific transporter ASCT2 (SLC1A5) 
and then undergoes different metabolic pathways, providing both carbon and nitrogen for the 
synthesis of novel aminoacids, nucleotides and lipids [143, 150]. For instance, Glu is metabolized 
into glutamate which, in turn, can be converted in α-ketoglutarate to fuel the TCA cycle and 
subsequent ATP production. The Glu-aspartate-oxaloacetate metabolic pathway was also reported 
to be activated in CSCs [143, 151].  
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   High expression levels of ASCT2 were found to be associated with stemness traits in cancer cells, 
while the knockdown of this receptor reduces the proportion of CSCs in tumors, such as colon 
cancer. An altered glutamine metabolism was observed in colon CSCs resistant to the activity of 
antitumor compounds, such as metformin; on the other hand, inhibition of glutamine metabolism 
restored the sensitivity of the stem cells to the drug [152]. Both glutamine synthetase and 
glutaminase 1 levels were reported to be higher in cancer stem cells when compared with the non-
stem cancer cells counterpart  [153, 154]. 
   A metabolic reprogramming was reported also for melanoma CSCs. We have previously 
demonstrated that melanoma cells escaping the antitumor activity of vemurafenib (the selective 
mutant-BRAF inhibitor) are characterized by stem cells features, such as the ability to form 
melanospheres when cultured in appropriate conditions [26, 45, 46, 155]. Melanoma cells that 
survive to the antitumor activity of BRAF and MEK inhibitors were shown to display an increased 
expression/activity of PGC1α, the factor well known to be responsible for increased mitochondrial 
biogenesis and subsequent mitochondrial OXPHOS activity [156-158]. Prolonged inhibition of 
BRAF was also reported to be associated with increased mitochondrial fusion (associated with 
decreased mitochondrial fission) and oxydative phosphorylation [158, 159]. Moreover, BRAF and 
MEK inhibitors are known to trigger the endoplasmic reticulum (ER) stress pathways leading to 
Ca2+ release from ER and its subsequent entry into mitochondria where it activates the enzymes 
specifically involved in the OXPHOS mechanism [158, 160]. Thus, according to these studies, cells 
resistant to BRAF and MEK inhibitors display enhanced mitochondrial biogenesis and fusion 
together with an increased ER-mitochondria Ca2+ axis; altogether, these mechanisms are 
responsible for an increased mitochondrial respiration in these cells. In line with these data, it was 
shown that melanoma cells resistant to vemurafenib display high OXPHOS associated with 
increased ROS production [128, 160]. Based on these observations, Sotgia and coworkers recently 
proposed the clinical utility of a 'mitochondrial based oncology platform' to specifically target 
cancer cell cells in different tumors, including melanoma [141]. 
   On the other hand, by means of a metabolomic analysis, melanoma cells expressing the stem cell 
marker ABCB5 were shown to display a high activity of the glycolytic pathway, together with 
increased membrane phospholipid metabolism and glutaminolysis [161]. Moreover, Luo and 
coworkers [162] reported that mitochondrial phosphoenolpyruvate carboxykinase 2 (PKC2) is 
downregulated in melanoma stem cells, leading to citrate release from the mitochondria and 
subsequent activation of the oxalacetate-malate-pyruvate (increased glycolysis) and acetyl-
CoA.fatty acid (fatty acids synthesis) pathways, associated with decreased mitochondrial OXPHOS. 
The same authors also reported that cytosolic PKC1 is upregulated in melanoma stem cells and this 
is linked to glucose consumption and activation of the glycolytic pathways [163]. A reduced 
mitochondrial activity, mediated by the β3-adrenoreceptor, associated with increased glycolysis in 
melanoma cells was also reported by Calvani and coworkers [164]. 
   Taken together, these observations strongly support that the specific involvement of the glycolytic 
vs. the mitochondrial pathways in the metabolic reprogramming of melanoma stem cells is still a 
matter of debate. 
   Melanoma stem cells also display an altered lipid metabolism. First of all, melanoma cells with a 
high lipid content were reported to possess a high metastatic behavior [165]. Melanoma initiating 
cells were shown to express the membrane receptor CD36, responsible for fatty acid uptake from 
the tumor microenvironment, and to obtain energy (ATP) by means of the lipid β-oxidation 
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pathways to support their self-renewal and metastatic properties [148]. CD133+ melanoma cells 
were demonstrated to have a high lipid content, specifically triglycerides and cholesteryl esters, 
together with accumulation of LD and increased synthesis of lipogenic genes, such as SREBP-1 
(sterol regulatory element-binding protein-1) and PPAR-γ (peroxisome proliferator-activated 
receptor-γ) [166]. These metabolic changes were found to be associated with a reduced autophagic 
axis [167].  
   CSCs are also characterized by high levels of monounsaturated fatty acids, produced by the key 
enzyme SCD1 (stearoyl-CoA desaturase 1). SCD1 was reported to be overexpressed in melanoma 
stem cells. Specifically, in melanoma cells resistant to MAPK inhibitors, the increased levels of 
SCD1 was associated with an upregulation of the Hippo pathway, through the activation of the 
nuclear adaptor factors YAP/TAZ known to be involved in the biological features of CSCs; 
inhibition of SCD1 reduced the percentage of MAPK-resistant stem cells by downregulating this 
pathway[168]. 
   Finally, the data so far available on the role of the glutamine metabolism in the biological features 
of melanoma stem cells are still very scanty and further studies are needed to definitively clarify 
this issue [131, 169, 170]. 
   Taken together, the results here summarized suggest that metabolic alterations in cancer stem 
cells might represent a novel interesting therapeutic target for most aggressive melanomas. 
 
7.  Intracellular signaling pathways in melanoma CSCs 
    
   As discussed above, CSCs are deeply involved in melanoma development and progression, EMT 
and angiogenesis/vasculogenic mimicry. Based on these biological properties, CSCs act as a key 
player in the development of drug resistance [8, 17, 171]; thus, the elucidation of the molecular 
pathways involved in melanoma CSCs protumorigenic activity might help increase the 
identification of novel molecular targets of new effective  therapeutic strategies.  
   Different  signaling pathways have been so far reported to be involved in melanoma CSC 
biological functions, such as TGFβ, Notch, Wnt/β-catenin, Hedghog (HH) [8, 171-174]; these 
pathways trigger the expression of EMT-TFs, responsible for the EMT phase and acquisition of 
stemness traits by cancer cells. 
    TGFβ (transforming growth factor beta) is known to be involved in the mechanisms of cell 
growth and differentiation and to play a key role in EMT and stemness in different types of cancers    
[175-177]. The binding of TGFβ to its receptors (TGFβ receptors I and II) induces their 
dimerization, leading to the phosphorylation of Smad2 and 3 and their association with Smad4; the 
transcription factors Smad2/3-Smad4 complexes translocate into the  nucleus where they regulate  
the expression of genes involved in tumor growth and progression. TGF β also interacts with 
different signaling pathways, such as p38 MAPK kinase, ERK, PI3K and Wnt/β catenin [178-180] 
and has been shown to be the most important paracrine factor produced by stroma cells in the 
cancer microenvironment [179, 181, 182] where it acts as a tumor-promoting factor [181]. TGFβ 
also triggers the switching from a non-stem to a cancer stem cell condition [183]. 
   In line with these observations, Lv and coworkers demonstrated that TGFβ secreted by 
mesenchymal stem cells induces B16 mouse melanoma cells metastatic behavior and this activity is 
mediated by the transcription factor Snail [184]. TGFβ was reported to induce EMT in melanoma 
cells accompanied by a decreased expression of MITF (a melanocyte differentiation marker) and an 
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increased expression of N-cadherin; TGF β treatment was also found to stimulate melanoma cells 
migratory and invasive behavior through activation of PDGF and its downstream signaling 
pathways (PI3K/Akt/PKB) [185]. Cantelli and coworkers reported that TGFβ and its downstream 
functional axis Smad2 and CITED1 (the Smad 2 adaptor) promote melanoma cell ameboid 
migration and attachment to endothelial cells, markers of cancer cell aggressiveness independent of 
EMT [186]. 
   Tumor associated macrophages (specifically the M2 subtype) sustain the proliferation and the 
stemness behavior of melanoma initiating cells and this effect is mediated by macrophage-secreted 
TGFβ [187]. Moreover, Nodal, a member of the TGFβ family, was shown to be activated in 
chemoresistant melanoma cells and to escape the antitumor activity of targeted therapies (i.e., 
BRAF inibitors) [188]. In metastatic melanoma cells, Nodal could also induce vasculogenic 
mimicry (a marker of melanoma cells plasticity) through the binding to and activation of TGFβ 
receptor II [189]. 
   IGF-1 is another growth factor deeply linked to cancer progression and expression of stemness 
traits in different types of tumors, including melanoma. IGF-1 can be produced by cancer cells or by 
cells of the tumor microenvironment, to act as either an autocrine or a paracrine stemness promoting 
factor [190]. Blockade of IGF-1 was shown to prevent melanoma cell metastatic behavior and the 
EMT process through downregulation of mesenchymal (Zeb1, CD44, CD29, N-cadherin) and 
stemness (Sox2, Oct3/4, CD133) markers as well as of features of the functional behavior of stem 
cells (ALDH activity, sphere formation) [81]. In line with these observations, Wang and coworkers 
demonstrated that overexpression of IGFBP5 inhibits melanoma cell metastatic features and this is 
accompanied by the suppression of stem cell markers, such as Nanog, Sox2, Oct4 and CD133. 
IGFBP5 also interferes with the activation of the IGF1 receptor and its downstream signaling 
pathways (ERK and p38-MAPK) as well as with the expression of HIF1α, MMP9 and VEGF, 
known to be crucial players in the EMT process in melanoma cells [82]. 
   The Notch receptors family comprises a group of cell surface receptors that are highly activated in 
cancer cells and specifically involved in the tumorigenic functions of CSCs. The expression of these 
receptors has been widely found to correlate with the expression of stem cell markers (i.e., ALDH1) 
in different types of cancer cells [173, 174, 191, 192]. It is well known that the Notch receptors 
signaling is dependent on the activity of the γ-secretase (GSI), a protease complex that is 
responsible for the cleavage of these receptors, thus releasing their active intracellular fragment 
(NCID, Notch Intracellular Domain). NCID then translocates into the nucleus to regulate the 
expression of different genes involved in CSCs features and functions [174].  
   Notch1 signaling has been reported to be overactivated in melanoma cells, acting as a driving 
factor in their metastatic progression; its expression correlates with the expression levels of nestin. 
Murtas and coworkers reported that Notch1 activation is involved in the ‘maintenance of 
melanocyte stem cells and associated vasculogenesis’ [193]. Notch1 activity was found to correlate 
with the expression of the CD133 stem cell marker in melanoma cells; in these cells, the expression 
of CD133 was shown to be regulated by NICD1. Interestingly, the Notch1/CD133 axis modulates 
the expression level of proteins involved in melanoma progression and metastasis, such as MMPs 
and VEGF, through the p38-MAPK pathway [87]. 
   Hsu and coworkers reported that Notch3 signaling increases the plasticity of melanoma cancer 
stem cells; in these cells, silencing of Notch3 induces a downregulation of CSC markers, such as 
CD271 and CD133 [194]. Finally, Notch4 was reported to be highly expressed in melanoma stem-
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like cells and to trigger metastasis through activation of the Twist/VE-cadherin/E-cadherin 
signaling pathway [195].  
   Several data from the literature support that the Wnt signaling pathway is deeply involved in the 
regulation of CSC features. Specifically, Wnt proteins are a family of 19 secreted glycoproteins that 
are involved, either in an autocrine or in a paracrine way, in the control of CSC expansion, self-
renewal, resistance, movement and polarity. These proteins were shown to act through the 
activation of both a canonical (β-catenin-mediated) and a non-canonical (β-catenin-unrelated) 
signaling pathway [171, 196-198]. The prominent role of the β-catenin-mediated pathway in cancer 
resistance and stemness, with respect to the non-canonical pathway, is now widely accepted. 
   Secreted Wnt (particularly Wnt2B and Wnt3 in CSCs) binds to the Frizzled receptor (Frz) which 
is complexed with its co-receptor LRP-5/6 (low density lipoprotein receptor-related 5/6). In the 
absence of Wnt ligand, β-catenin (bound to axin) is phosphorylated by CK1 (casein kinase 1) and  
GSK3 (Glycogen Synthase Kinase 3), resulting in its ubiquitination and proteasomal degradation. 
[199]. When Wnt binds to the receptor complex, axin is recruited to the membrane together with 
LRP5/6 and Disheveled, thus interrupting β-catenin degradation. Stabilized β-catenin can now enter 
the nucleus where it displaces co-repressor proteins and transcription factors, such as Groucho and 
TCF/LEF, triggering the transcription of its target genes. Genes activated by β-catenin are deeply 
involved in the EMT program and development of resistance and include Twist, Slug, Snail, 
vimentin, and the transporter ABCG2 [171, 196-198]. However, it must be underlined that a 
positive correlation of this pathway with melanoma progression has been recently questioned [200]. 
   Hedgehog (HH) is another signaling pathway involved in EMT and CSC features. [201]. In the 
absence of the ligand, HH receptors are linked to the membrane protein Smoothened (Smo). In this 
condition, the HH effector proteins (Gli, Glioma-associated oncogene homolog) are phosphorylated 
and subsequently degraded at the proteasomal level. After the binding of HH protein to the receptor, 
Smo is activated and triggers the activity of Gli, especially Gli1, responsible for the induction of 
stem cell and of EMT markers [202]. Santini and coworkers reported that the HH pathway is highly 
activated in melanoma stem cells; on the other hand, targeting Smo or Gli1 by means of specific 
antagonists results in decreased stem cell features, such as melanosphere formation and ALDH 
expression [203].  
   The embryonic stem cell marker Sox2 is highly expressed in melanoma stem cells and is deeply 
involved in their stemness behavior and features; in these cells, Sox2 was found to be upregulated 
by Gli1 and Gli2 at the transcriptional level [204]. Thus, the HH signaling pathway may represent 
an additional molecular target for anticancer compounds (including natural compounds) specifically 
acting by depleting the stem cell subpopulations in tumors [205]. 
8.  Melanoma CSCs as novel therapeutic strategies 
   A major challenge of the current therapies for solid tumors, such as chemotherapy and 
radiotherapy, is represented by the development of resistance to drugs and tumor recurrence. 
Different molecular mechanisms were proven to be involved in therapeutic resistance, such as: 
increased drug metabolism and drug efflux (mainly related to increased expression of drug 
transporters); enhanced repair capacity of damaged DNA; reactivation of drug targets; 
overactivation of growth and survival signaling pathways; amplification of genetic mutations; 
impaired activity of the apoptosis/autophagy pathways [206, 207]. Tumor heterogeneity is another 
well accepted key driver of drug resistance in cancer patients [208, 209]. In particular, in contrast to 
AC
CE
PT
ED
 M
AN
US
CR
IPT
15 
 
the bulk of tumor cells, the subpopulation of CSCs has been widely shown to possess specific 
features that allow them to escape the antitumor activity of cytotoxic therapies in different types of 
cancers [58, 210-213].  
   CSCs, at their membrane level, express different members of the family of 'ATP-binding cassette 
(ABC) transporters' (ABCB5, ABCG1, ABCG2, ABCG5), a family of 'efflux pumps' that are able 
to bind and extrude drugs (such as chemotherapeutics) from the cells into their microenvironment. 
These proteins were reported to be expressed in CSCs and to be involved in the mechanisms of their 
survival to cytotoxic agents [214-216].   
   In addition to the ABC transporters, high levels of ALDH activity were observed in cells resistant 
to classical antitumor drugs, such as taxanes, cyclophosphamide, doxorubicin; mechanistically, 
ALDH was reported to catalyze the metabolism of these drugs into inactive compounds, thus 
making the cells resistant to treatments [212, 217, 218].  
   CSCs were shown to resist to chemotherapy by overexpressing factors involved in the regulation 
of the apoptosis pathways, such as the anti-apoptotic protein Bcl-2, through activation of the 
Notch/Hedgehog signaling [219, 220]. Moreover, some environmental conditions, such as tumor-
associated vasculature and hypoxia, can selectively promote CSC survival and proliferation [210]. 
    CSCs were also shown to be resistant to radiation therapy, mainly based on their ability to repair 
damaged DNA; these observations derive from studies performed in glioblastoma cells, since 
radiation therapy is the treatment of choice for this type of tumor. It was found that glioblastoma 
cells expressing the stem marker CD133 can efficiently repair radiation-induced DNA damage, 
through activation of checkpoint kinases CHK1 and CHK2; moreover, radiation treatment 
selectively kills the bulk of tumor cells while sparing CD133 positive cells in in vitro as well as in 
in vivo (xenografts derived from patients cells) [221]. In addition, radiation therapy can induce the 
formation of reactive oxygen species (ROS), responsible for DNA damage and apoptosis. CSCs 
escape these effects by inducing a constitutive up-regulation of ROS scavengers [222].   
   Taken together, these observations strongly support that CSCs represent a very attractive target 
for novel treatment strategies; the combined use of standard therapies directed against the bulk of 
tumor cells and compounds that specifically target the CSCs subpopulation might significantly 
improve the therapeutic opportunities for cancer patients. 
   CSCs were widely reported to be involved also in the development of resistance to standard 
therapies ( 'targeted therapies', such as vermurafenib, dabrafenib, binimetinib; chemotherapies, such 
as dacarbazine, taxanes) in melanomas. We recently showed that treatment of BRAF-mutated A375 
melanoma cells with vemurafenib dose-dependently inhibits cell viability; interestingly, we found 
that cells escaping the anticancer activity of the compound showed a high ability to form 
melanospheres [26, 45, 46], a specific CSC feature. In a series of BRAF-mutated melanoma cells, 
resistance to BRAF and MEK inhibitors was demonstrated to be associated with increased 
expression of the transcription factor Sox2, known to be involved in cancer cell stemness, and its 
downstream target CD24, a protein associated with cancer cells aggressiveness and that specifically 
localizes in membrane lipid rafts where it interacts and activates Src-kinases  [49]. BRAF-mutated 
melanoma cells escaping the antitumor activity of vemurafenib and binimetinib were reported to be 
associated with enhanced expression of the YAP/TAZ stem cell markers [168]. Cordaro and 
coworkers demonstrated that melanoma cells made resistant to dabrafenib were found to exhibit 
stemness features, associated with activation (nuclear translocation) of the transcription factor Oct4 
and subsequent increased expression of CD20, a specific melanoma stem cells marker [223]. 
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   Similar observations were reported in melanoma cells resistant to chemotherapeutic drugs. For 
instance, taxol was found to increase the activity of the ERK pathway in CD133+ (but not CD133-) 
melanoma cells [224]; moreover, in mouse B16F10 melanoma cells, resistance to paclitaxel was 
shown to be associated with the expression of ABCB5; a combination treatment with paclitaxel and 
a short-interfering RNA against ABCB5 significantly suppressed tumor growth escaping the 
development of resistance [225]. Interestingly, in the same murine cell line, the chemotherapeutic 
dacarbazine induced upregulation of the subpopulation of CD133 positive cells and increased the 
'vasculogenic mimicry' property of these cells [97] Recently, integrin β3 has been suggested as a 
novel marker of cell stemness. Zhu et al. reported that, in both murine and human melanoma cells, 
development of resistance to doxorubicin and methotrexate is associated with increased expression 
of integrin β3; cotreatment of the cells with chemoterapeutic drugs and an inhibitor of this integrin 
was able to kill melanoma cells and to reverse drug resistance [226]. 
   Based on these observations, targeting the specific biological features of melanoma stem cells 
(i.e., expression of stemness markers, molecular pathways involved in self-renewal, metabolic 
alterations) might represent an effective therapeutic strategy to eradicate this aggressive cell 
subpopulation and overcome drug resistance. 
   CD20 is a well known cell surface marker of melanoma cells stemness. Schmidt and coworkers 
reported that specific targeting of CD20+ melanoma cells induce a complete eradication of tumor 
lesions in vivo [227]. In melanoma patients resistant to chemotherapeutic drugs, intra-tumoral 
injections of rituximab, the specific antibody against CD20, promoted a regression of tumors 
growth, accompanied by a significant decrease of serum inflammatory markers [228]. Interestingly, 
liposomes conjugated with CD20 antibodies and loaded with vincristin, a well known anti-
melanoma drug that specifically targets the bulk of tumor cells without affecting the CSCs 
subpopulation, were found to significantly decrease the growth of melanospheres in vitro and in 
vivo in xenografted mice [229]. More recently, Zeng et al. developed salinomycin-loaded lipid 
polymer nanoparticles linked to anti-CD20 aptamers. The aim of this drug design was to 
specifically target salinomycin, a compound characterized by a poor solubility, to CD20-positive 
melanoma stem cells. These aptamers were efficiently uptaken into CD20+ melanoma cells, 
exerting a significant cytotoxic activity against these cells and reducing their ability to form 
melanospheres. These results were further confirmed in preclinical studies (nude mice xenografted 
with melanoma cells and treated with the nanoparticles) [230]. 
   By short interfering RNA, in in vitro and in vivo experiments, it was observed a downregulation 
of CD133+ in FEMX-I highly metastatic melanoma cells associated with a significant decrease in 
cell proliferation, metastatic behavior and ability to form melanospheres. Similar results were 
obtained with antibodies specifically targeting CD133 [231]. CD133+ melanoma cells were reported 
to resist to the antitumor activity of the bioactive compound CAPE, caffeic acid phenylester, 
through an upregulation of the drug transporter ABCB5; silencing this membrane pump resensitized 
the cells to the antitumor activity of CAPE [232]. Bostad et al. utilized the 'phytochemical 
internalization' technique to further support the role of CD133 as a molecular target of antitumor 
strategies specifically targeting CSCs [233]. The AC133-saporin is an immunotoxin formed by a 
complex formed by a biotinylated monoclonal antibody against CD133 (AC133) linked to saporin. 
In their work, Bostad and coworkers entrapped this complex into endocytic vesicles that were 
specifically uptaken into FEMX-1 melanoma cells expressing CD133 to form endosomes. By using 
the 'phytochemical internalization' technique, they could induce the disruption of the endolysosomal 
AC
CE
PT
ED
 M
AN
US
CR
IPT
17 
 
membranes, thus leading to the release of the free cytotoxic compound in the cytoplasm. AC133-
saporin specifically inhibited the proliferation of the subpopulation of melanoma cells expressing 
the surface CD133+ marker [233]. Melanoma cells expressing this marker were also reported to 
express the VEGF receptor (VEGF-R2). Treatment of these cells with both the cytotoxic drug 
etoposide and the antiangiogenic compound bevacizumab significantly reduced their ability to form 
melanospheres in vitro and to give rise to lung metastasis in vivo [234]. More recently, the 
polyphenol morin, isolated from members of the Moraceae family of plants and extracted from 
woods, was shown to decrease the growth and sphere formation ability as well as the expression of 
different surface markers of stemness (CD133, CD20 and CD44) in melanoma cells by inducing the 
expression of miR-216a and subsequent downregulation of Wnt-216a expression levels [235]. 
   Nanoparticles coated with hyaluronic acid, a specific ligand of the marker CD44, and loaded with 
the chemotherapeutic drug paclitaxel, significantly inhibited CD44+ stem cells by inducing 
apoptosis, in vitro and in vivo [236]. It is known that some tumor cells, at their membrane level, 
overexpress CD47, an integrin-associated protein which can bind to a specific receptor expressed on 
macrophages, to counteract their phagocytic activity. Interestingly, a cotreatment with antibodies 
targeting CD47 and  the stemness marker CD271 significantly counteracts tumor metastasis 
formation in melanoma patient-derived cells xenografted in nude mice [64]. 
   As discussed above, the reliability of surface markers has been recently questioned, stimulating 
the search for novel markers of stemness in cancer cells. In a recent paper, we demonstrated that 
melanoma cells with stemness features are characterized by high fluorescence [26], possibly due to 
the presence of  riboflavin in vesicles coated with the transporter ABCG2 as previously reported by 
Miranda-Lorenzo and coworkers [44]. In this paper, we also demonstrated that the natural 
compound delta-tocotrienol (-TT) triggers the disaggregation of melanospheres and counteracts 
the ability of melanoma stem cells to form melanospheres, by decreasing the expression of ABCG2 
[26]. 
   Another effective marker of stemness is ALDH. In a recent paper by Sarvi et al., it has been 
shown that ALDH1 is able to bio-activate nifuroxazide, belonging to the family of 5-nitrofuranes; 
interestingly, activated nifuroxazide specifically targets the ALDH1high  melanoma cells by reducing 
their stemness properties [237].  
   Both synthetic and natural compounds were reported to affect the survival and self-renewal of 
melanoma CSCs by targeting stemness-associated transcription factors, such as Nanog, Sox2 and 
Oct4 [238-240] as well as intracellular signaling pathways involved in CSC growth (such as Notch 
and Wnt/β-catenin) and apoptosis (such as Bcl-2 and Bad) [197, 241-245]. A high efficiency in 
killing CSCs was observed by treating melanoma cells with Bcl-2 inhibitors together with a retinoid 
derivative (fenretinide) [246] or with an inhibitor of γ-secretase (GSI) [247]. 
   A key role of the Wnt pathway has been described in melanoma CSCs [248]. This pathway was 
shown to serve as an effective molecular target of different natural or synthetic compounds. The 
polyphenol morin (3,5,7,2',4'-pentahydroxyflavone) was reported to inhibit the proliferation, self-
renewal and sphere formation ability of melanoma cells expressing stem cells markers (CD133, 
CD44, CD20) by downregulating Wnt-3 through increased expression of MiR-216a [235]. 
Pimozide is an antipsychotic compound shown to possess also anticancer activity in different types 
of tumors, including melanoma [249]. Pimozide has been shown to exert its activity by targeting the 
Wnt/ β-catenin signaling pathway [250]. Liu and coworkers recently demonstrated that the 
compound 35b, a derivative from the natural chemical scaffold of symplostatin, affects the stem 
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cells traits (ALDH, sphere formation ability) of melanoma cells by interfering with the activity of 
the Wnt/β-catenin pathway [245]. 
   As stated above, a rewiring of mitochondrial biogenesis and activity is a key characteristic of 
melanoma CSCs. Lamb and coworkers demonstrated that 'mitochondrial-targeted antibiotics 
(tetracyclins, erythromycins, glycylcyclines), reported to be devoid of side effects in normal cells, 
specifically eradicate CSCs supporting their efficacy for preventive strategies. These results were 
further supported by clinical trials [251]. In line with this observation, Sotgia et al. recently 
suggested the relevance of the treatment of melanoma cells with 'mitochondrial-based oncology 
platforms, MITO-ONC-RX' to specifically target the CSC subpopulation in tumors [139, 141]. 
   Taken together, from the data so far available the literature it is clear that targeting the CSC 
subpopulation represents an attractive strategy to increase the therapeutic options for melanoma 
patients, independently of their genetic mutations. 
 
9.  Concluding remarks 
  
   Cutaneous melanoma still represents the cause of the majority of cancer-related deaths among 
skin cancer patients. It is characterized by a high cell heterogeneity, responsible for its frequent 
development of resistance to standard therapies. CSCs are a small, slow-cycling subpopulation of 
cells present in different tumors, including melanoma. These cells are characterized by self-renewal 
capacity and a high ability to proliferate and differentiate thus sustaining the initiation and the 
growth of the tumor mass. CSCs were widely reported to play a key role in the mechanisms of drug 
resistance; for this reason, the identification/isolation of CSCs and the characterization of their  
molecular, biological and functional features is now considered a crucial step for the improvement 
of anticancer strategies.  
   From the molecular point of view, melanoma CSCs are characterized by the expression of: 
surface markers of indifferentiation state (CD271 and CD133), ABC transporters involved in drug 
efflux, intracellular metabolic markers (ALDH enzymes) and embryonic stem cell markers (Sox2, 
Oct4, Nanog). However, it must be underlined that the reliability of surface markers has recently  
become a matter of debate. To overcome this problem, additional markers of stemness were 
investigated. It was found that a subpopulation of cells associated with autofluorescence, and the 
expression of the ABCG2 transporter, is present in melanoma cell lines, pointing out an additional 
potential stemness marker. Melanoma CSCs are able to form spheres when cultured in appropriate 
conditions and to give rise to the original tumor mass when xenografted in nude mice. 
   From the biological point of view, melanoma CSCs are associated with different functional 
features. They play a critical role in the process of tumor dissemination, based on the observation of 
their presence both in the blood and at the level of metastatic tissues of melanoma patients. 
Moreover, the tumor progression toward the EMT stage is characterized by the de-differentiation of 
tumor bulk cells into cells with stemness traits. Melanoma CSCs are also deeply involved in the 
process of angiogenesis through different mechanisms: expression of proangiogenic factors, trans-
differentiation into endothelial cells (vascular or vasculogenic mimicry) and migration moving 
along the abluminal vascular surface (pericytic mimicry). Similarly to other tumors, melanomas are 
often associated with escape from the immune system, due to a low-immunogenic profile and/or 
immunosuppressive properties. Specifically, melanoma CSCs were shown to be associated with a 
low-immunogenic profile, due to a very low expression of tumor associated antigens, and with the 
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ability to evade the immune system, by expressing factors involved in the negative regulation of T 
cell activation and by secreting immunosuppressive molecules. These cells also display a specific 
metabolic reprogramming. 
   Both these molecular and functional traits of melanoma CSCs, associated with specific 
intracellular signaling pathways, are known to be deeply involved in the key role of this 
subpopulation of tumor cells in the development of drug resistance. Based on these observations, 
CSCs are now considered an attractive target for innovative therapeutic interventions. Specifically, 
combination treatments based on both CSCs-targeting drugs together with standard treatments may 
offer the opportunity to definitely eradicate all the tumor cells subpopulations. Moreover, further 
studies aimed at increasing the opportunity to isolate and characterize melanoma CSCs in single 
patients are urgently needed to improve both the prognostic and the therapeutic strategies in terms 
of personalized medicine.    
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Figure captions: 
 
Figure 1. Melanoma CSCs and tumor progression. CSCs are deeply involved in melanoma 
dissemination, as demonstrated by their presence both in the patients circulation and at metastatic 
sites. CSCs are also involved in the processes of epithelial-to-mesenchymal transition (EMT) and 
angiogenesis. It is now established that two different EMT programs are activated during tumor 
progression. According to the classical theory, tumor bulk cells can acquire mesenchymal traits that 
allow them to detach from the tumor mass and give rise to dissemination. In addition, a 
subpopulation of tumor cells can de-differentiate into cells with CSCs features; these cells invade 
the extracellular matrix, enter (intravasation) the blood vessels from which they exit (extravasation) 
to colonize distant organs. This second program of EMT in melanoma is schematized in this figure. 
Melanoma CSCs also play a key role in the process of angiogenesis through different mechanisms: 
1) they express and secrete the main proangiogenic factors (i.e., VEGF) in the tumor 
microenvironment; 2) they can trans-differentiate into endothelial-like cells giving rise to an 
alternative microvascular circulation (vascular or vasculogenic mimicry); 3) they migrate moving in 
a pericytic-like manner along the surface of blood vessels (extravascular vasation migratory 
metastasis, EVMM), thus reaching distant metastatic tissues. 
 
 
Figure 2. Immunogenic properties of melanoma CSCs. Melanoma cells can elicit antitumor 
immune responses by recruiting innate (early phases) and adaptive (late phases) immune cells. The 
secretion of cytokines and chemokines by cancer cells leads to the infiltration of antitumor 
macrophages (M1) and neutrophils (N1). The overexpression of tumor-associated antigens (TAAs) 
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leads to the recruitment of professional antigen-presenting cells (dendritic cells), that in turn 
activate effector B and T cells against tumor cells. The expression of TAAs can be accompanied by 
the expression of MHC-I (Major Histocompatibility Complex-I) on melanoma cells, that leads to 
the direct recruitment of T cells. On the other hand, melanoma CSCs are able to evade 
immunosurveillance through the secretion of cytokines involved in the recruitment of protumor 
immune cells, through the overexpression of immunomodulatory molecules such as checkpoint 
proteins involved in the negative regulation of T cells (PD-L1), and through the secretion of 
proapoptotic factors such as FasL. MDSC, myeloid-derived suppressor cells; Treg, regulatory T 
cells; Th17, T helper 17 cells. 
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